244 related articles for article (PubMed ID: 27380995)
1. Long-term endurance and safety of elosulfase alfa enzyme replacement therapy in patients with Morquio A syndrome.
Hendriksz CJ; Parini R; AlSayed MD; Raiman J; Giugliani R; Solano Villarreal ML; Mitchell JJ; Burton BK; Guelbert N; Stewart F; Hughes DA; Berger KI; Slasor P; Matousek R; Jurecki E; Shaywitz AJ; Harmatz PR
Mol Genet Metab; 2016 Sep; 119(1-2):131-43. PubMed ID: 27380995
[TBL] [Abstract][Full Text] [Related]
2. Long-term Immunogenicity of Elosulfase Alfa in the Treatment of Morquio A Syndrome: Results From MOR-005, a Phase III Extension Study.
Long B; Tompkins T; Decker C; Jesaitis L; Khan S; Slasor P; Harmatz P; O'Neill CA; Schweighardt B
Clin Ther; 2017 Jan; 39(1):118-129.e3. PubMed ID: 27955919
[TBL] [Abstract][Full Text] [Related]
3. Multi-domain impact of elosufase alfa in Morquio A syndrome in the pivotal phase III trial.
Hendriksz CJ; Giugliani R; Harmatz P; Mengel E; Guffon N; Valayannopoulos V; Parini R; Hughes D; Pastores GM; Lau HA; Al-Sayed MD; Raiman J; ; Yang K; Mealiffe M; Haller C
Mol Genet Metab; 2015 Feb; 114(2):178-85. PubMed ID: 25284089
[TBL] [Abstract][Full Text] [Related]
4. Clinical outcomes in a subpopulation of adults with Morquio A syndrome: results from a long-term extension study of elosulfase alfa.
Hughes D; Giugliani R; Guffon N; Jones SA; Mengel KE; Parini R; Matousek R; Hawley SM; Quartel A
Orphanet J Rare Dis; 2017 May; 12(1):98. PubMed ID: 28535791
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of enzyme replacement therapy with BMN 110 (elosulfase alfa) for Morquio A syndrome (mucopolysaccharidosis IVA): a phase 3 randomised placebo-controlled study.
Hendriksz CJ; Burton B; Fleming TR; Harmatz P; Hughes D; Jones SA; Lin SP; Mengel E; Scarpa M; Valayannopoulos V; Giugliani R; ; Slasor P; Lounsbury D; Dummer W
J Inherit Metab Dis; 2014 Nov; 37(6):979-90. PubMed ID: 24810369
[TBL] [Abstract][Full Text] [Related]
6. Safety and physiological effects of two different doses of elosulfase alfa in patients with morquio a syndrome: A randomized, double-blind, pilot study.
Burton BK; Berger KI; Lewis GD; Tarnopolsky M; Treadwell M; Mitchell JJ; Muschol N; Jones SA; Sutton VR; Pastores GM; Lau H; Sparkes R; Genter F; Shaywitz AJ; Harmatz P
Am J Med Genet A; 2015 Oct; 167A(10):2272-81. PubMed ID: 26069231
[TBL] [Abstract][Full Text] [Related]
7. Impact of long-term elosulfase alfa on activities of daily living in patients with Morquio A syndrome in an open-label, multi-center, phase 3 extension study.
Hendriksz CJ; Parini R; AlSayed MD; Raiman J; Giugliani R; Mitchell JJ; Burton BK; Guelbert N; Stewart FJ; Hughes DA; Matousek R; Hawley SM; Decker C; Harmatz PR
Mol Genet Metab; 2018 Feb; 123(2):127-134. PubMed ID: 29248359
[TBL] [Abstract][Full Text] [Related]
8. Safety, immunogenicity, and clinical outcomes in patients with Morquio A syndrome participating in 2 sequential open-label studies of elosulfase alfa enzyme replacement therapy (MOR-002/MOR-100), representing 5 years of treatment.
Hendriksz C; Santra S; Jones SA; Geberhiwot T; Jesaitis L; Long B; Qi Y; Hawley SM; Decker C
Mol Genet Metab; 2018 Apr; 123(4):479-487. PubMed ID: 29526614
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity of Elosulfase Alfa, an Enzyme Replacement Therapy in Patients With Morquio A Syndrome: Results From MOR-004, a Phase III Trial.
Schweighardt B; Tompkins T; Lau K; Jesaitis L; Qi Y; Musson DG; Farmer P; Haller C; Shaywitz AJ; Yang K; O'Neill CA
Clin Ther; 2015 May; 37(5):1012-1021.e6. PubMed ID: 25487082
[TBL] [Abstract][Full Text] [Related]
10. Impact of elosulfase alfa in patients with morquio A syndrome who have limited ambulation: An open-label, phase 2 study.
Harmatz PR; Mengel E; Geberhiwot T; Muschol N; Hendriksz CJ; Burton BK; Jameson E; Berger KI; Jester A; Treadwell M; Sisic Z; Decker C
Am J Med Genet A; 2017 Feb; 173(2):375-383. PubMed ID: 27774754
[TBL] [Abstract][Full Text] [Related]
11. Safety and clinical activity of elosulfase alfa in pediatric patients with Morquio A syndrome (mucopolysaccharidosis IVA) less than 5 y.
Jones SA; Bialer M; Parini R; Martin K; Wang H; Yang K; Shaywitz AJ; Harmatz P
Pediatr Res; 2015 Dec; 78(6):717-22. PubMed ID: 26331768
[TBL] [Abstract][Full Text] [Related]
12. Impact of long-term elosulfase alfa treatment on respiratory function in patients with Morquio A syndrome.
Hendriksz CJ; Berger KI; Parini R; AlSayed MD; Raiman J; Giugliani R; Mitchell JJ; Burton BK; Guelbert N; Stewart F; Hughes DA; Matousek R; Jurecki E; Decker C; Harmatz PR
J Inherit Metab Dis; 2016 Nov; 39(6):839-847. PubMed ID: 27553181
[TBL] [Abstract][Full Text] [Related]
13. Elosulfase Alfa: a review of its use in patients with mucopolysaccharidosis type IVA (Morquio A syndrome).
Lyseng-Williamson KA
BioDrugs; 2014 Oct; 28(5):465-75. PubMed ID: 25200032
[TBL] [Abstract][Full Text] [Related]
14. Minimal clinically important difference for the 6-min walk test: literature review and application to Morquio A syndrome.
Schrover R; Evans K; Giugliani R; Noble I; Bhattacharya K
Orphanet J Rare Dis; 2017 Apr; 12(1):78. PubMed ID: 28441951
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic and pharmacodynamic evaluation of elosulfase alfa, an enzyme replacement therapy in patients with Morquio A syndrome.
Qi Y; Musson DG; Schweighardt B; Tompkins T; Jesaitis L; Shaywitz AJ; Yang K; O'Neill CA
Clin Pharmacokinet; 2014 Dec; 53(12):1137-47. PubMed ID: 25234648
[TBL] [Abstract][Full Text] [Related]
16. Longitudinal analysis of endurance and respiratory function from a natural history study of Morquio A syndrome.
Harmatz PR; Mengel KE; Giugliani R; Valayannopoulos V; Lin SP; Parini R; Guffon N; Burton BK; Hendriksz CJ; Mitchell JJ; Martins AM; Jones SA; Guelbert N; Vellodi A; Wijburg FA; Yang K; Slasor P; Decker C
Mol Genet Metab; 2015 Feb; 114(2):186-94. PubMed ID: 25582974
[TBL] [Abstract][Full Text] [Related]
17. Elosulfase alfa (BMN 110) for the treatment of mucopolysaccharidosis IVA (Morquio A Syndrome).
Hendriksz CJ
Expert Rev Clin Pharmacol; 2016 Dec; 9(12):1521-1532. PubMed ID: 27855521
[TBL] [Abstract][Full Text] [Related]
18. Findings from the Morquio A Registry Study (MARS) after 6 years: Long-term outcomes of MPS IVA patients treated with elosulfase alfa.
Mitchell JJ; Burton BK; Bober MB; Campeau PM; Cohen S; Dosenovic S; Ellaway C; Bhattacharya K; Guffon N; Hinds D; Lail A; Lin SP; Magner M; Raiman J; Schwartz-Sagi L; Stepien KM
Mol Genet Metab; 2022; 137(1-2):164-172. PubMed ID: 36087504
[TBL] [Abstract][Full Text] [Related]
19. [Morquio disease (Mucopolysaccharidosis type IV-A): clinical aspects, diagnosis and new treatment with enzyme replacement therapy].
Politei J; Schenone AB; Guelbert N; Fainboim A; Szlago M
Arch Argent Pediatr; 2015 Aug; 113(4):359-64. PubMed ID: 26172013
[TBL] [Abstract][Full Text] [Related]
20. Cardiopulmonary Exercise Testing Reflects Improved Exercise Capacity in Response to Treatment in Morquio A Patients: Results of a 52-Week Pilot Study of Two Different Doses of Elosulfase Alfa.
Berger KI; Burton BK; Lewis GD; Tarnopolsky M; Harmatz PR; Mitchell JJ; Muschol N; Jones SA; Sutton VR; Pastores GM; Lau H; Sparkes R; Shaywitz AJ
JIMD Rep; 2018; 42():9-17. PubMed ID: 29159458
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
